Trulieve ($TRLV): Can Medical Cash Support Growth and Tax Risk?

01 Scenarios for Trulieve’s medical platform

What Would Falsify This Reading

Sustained cash growth from the current reporting perimeter, after ordinary investment and a transparent treatment of tax payments, would weaken the caution about financial flexibility. Conversely, worsening collection of management-service receivables, further write-downs of the retained investment, or a material adverse tax development would undermine a favorable view. Final Texas approval is a commercial milestone; an agreement covering that state is not evidence that sales have started.

02 What Trulieve owns after the Harvest separation

Trulieve cultivates, processes and sells medical cannabis through a regulated network. Vertical integration means that a portion of the retail margin and the manufacturing margin stay within the group. It also means that the company carries the cost of growing facilities, product testing, inventory, distribution and dispensary staffing before the customer purchase becomes cash. The retail network is valuable only when its demand and production economics support that infrastructure.

At June 30, 2026, the consolidated medical network had 206 dispensaries: 169 in Florida, 21 in Pennsylvania, 10 in West Virginia and six in Georgia, according to the quarterly operating table. Quarterly report, MD&A The same table lists ten cultivation and processing facilities across those states. Quarterly report, MD&A, June 30, 2026 These are the consolidated medical operations, not a current count that silently adds the separate Harvest network.

The annual report described 233 dispensaries across the wider group at December 31, 2025. Annual report, business overview Comparing that historical total directly with the medical-only June network would describe a change in accounting perimeter as though it were a series of store closures. The underlying explanation is the separation of the mixed-use businesses. Locations, licenses and revenues outside the consolidated boundary require their own treatment.

Retail accounted for 94% of revenue in the quarter ended June 30, 2026, according to the earnings release. August 7, 2026 results That concentration explains why patient traffic, repeat orders, realized selling prices and store-level expenses matter more than a broad description of the cannabis addressable market. A vertically integrated medical operator does not earn revenue from every eligible patient in a state, and a new permitted product category does not guarantee that an existing patient spends more.

The annual description of cultivation economics explains that cost of goods sold includes production labor and materials, allocated overhead, utilities, rent and depreciation associated with cultivation and processing. Annual report, MD&A for the year ended December 31, 2025 Gross profit is therefore not a contribution measure that excludes the physical platform. Still, retail staffing and much corporate spending remain below gross profit. Reading both levels prevents a high gross margin from being confused with final profitability.

Florida is the central operating concentration. Its network can support production scale and convenient access, but concentration makes local pricing, regulation, weather and patient demand disproportionately important. Geographic expansion can diversify that exposure only after the new operations establish adequate economics. Early expansion can instead add cost while the established market continues to fund the group.

03 Harvest’s retained interest is not ordinary consolidated ownership

The June 3 agreement identifies Whitley Holding 05192026, LLC as the Harvest investor. It acquired voting units carrying a 10% economic interest for approximately $14.8 million and appointed Frank Whitley and Rudy Rowe to the Harvest board; Trulieve’s subsidiary appointed Kim Rivers. Trulieve SEC filing, June 2026.

On June 3, 2026, Trulieve deconsolidated Harvest’s mixed medical and adult-use operations through agreements that separated them from the medical business supporting the NYSE listing. June 4, 2026 filing This is an accounting and governance change with economic consequences. It cannot be understood merely by describing Harvest as a subsidiary that remains inside the group.

The retained non-voting, non-participating units do not currently carry ordinary voting rights, dividend rights or liquidation participation. They can convert into common units only after the exchange permits listings of companies that consolidate the relevant non-medical cannabis operations. June 4, 2026 filing The conditional conversion preserves a potential future economic interest; it does not give Trulieve present control of the mixed-use business.

Under the June 3, 2026 arrangements, the independent investor acquired voting units representing a 10% economic interest for approximately US$14.8 million, and appoints two Harvest board managers while Trulieve appoints one. June 4, 2026 filing The filing says that, following conversion of the retained units, Trulieve cannot hold more than 90% of the units. June 4, 2026 filing Neither the investor’s purchase nor the retained-interest valuation is evidence of sale proceeds received by the listed parent; that would require a supporting cash-flow statement.

The June 30, 2026 accounts measured the initially retained interest at US$155.792 million and derecognized US$559.125 million of net assets, producing a US$403.333 million deconsolidation loss. Quarterly report, Note 4 This is primarily the difference between the old carrying amount and the fair value of the interest that remains. It is not an invoice for the same amount paid during the quarter.

By June 30, 2026, the investment’s carrying value was US$152.503 million after US$3.289 million of equity-method loss. Quarterly report, Notes 4 and 5 Equity-method accounting brings Trulieve’s share of the investee result into the income statement; it does not restore Harvest revenue, operating costs or cash to the consolidated line items.

The valuation also depends on judgment. The June 30, 2026 note uses a discount rate of 11%, projected EBITDA margins of 22.8%–25.1% and a marketability discount of 23.5%. Quarterly report, Note 5 Those are valuation assumptions, not published achieved margins or a promise of future returns. If the investee performs worse or the assumptions change, the retained asset can lose value even when no immediate cash payment occurs.

A protective covenant can preserve rights without conveying control. Likewise, a service contract can generate fees without making the service recipient a consolidated business. The useful question is which rights Trulieve can exercise now, which depend on a future event and which claims can generate collectible cash.

04 Management services create a separate collection question

The management-services arrangement keeps an operating connection between Trulieve and Harvest after deconsolidation. Consulting, advisory and administrative support can preserve practical efficiencies while the companies report separately. That does not make the arrangement economically identical to owning and consolidating the customer.

The June 30, 2026 quarterly note describes reimbursement of costs plus a 5% margin and a fixed quarterly fee under the management-services agreement. Quarterly report, Notes 4 and 5 The June filing also describes a cap on the cost-plus arrangement and the ability of either party to terminate on 90 days’ notice. June 4, 2026 filing The arrangement has contractual terms and termination risk, rather than an unlimited permanent entitlement to Harvest’s operating cash.

For the quarter and half-year ended June 30, 2026, reported management-services revenue was approximately US$1.7 million, while the related-party receivable at June 30 was US$22.945 million. Quarterly report, Notes 4 and 5 and balance sheet Those figures measure different things. The receivable is not pure fee revenue, nor a fee multiplied by the number of months, because reimbursement and settlement balances can have a different scope.

The next financial disclosures will be the place to watch collections and the evolution of that balance. Revenue recognition demonstrates that services have been recorded under the contract. Cash collection demonstrates that the related party can settle the obligation. A growing receivable can absorb resources even when the contractual margin remains attractive.

At June 30, 2026, the filing described approximately US$175.4 million of maximum exposure through the Harvest investment and related management-services receivable, with no committed guarantees or liquidity support. Quarterly report, Note 5 The absence of a guarantee limits a particular legal obligation; it does not make the investment or the receivable riskless. Their value still depends on the investee’s business and its ability to pay.

The practical distinction is between an accounting perimeter and an economic connection. Deconsolidation removes the investee’s liabilities from the parent’s line-by-line accounts, but the listed company retains an asset whose value can decline and a receivable whose collection can take time. A cleaner medical-only presentation must therefore be read alongside the retained exposure rather than as complete isolation from the mixed-use business.

This connection also affects future comparisons. Fees can enter consolidated revenue while the former operating revenue no longer does. A change in the fee line is not the organic performance of the old retail network. The company needs to disclose enough of the bridge for readers to understand both the current medical operation and the residual relationship.

05 Revenue comparisons require a reporting-perimeter bridge

For the quarter ended June 30, 2026, Trulieve reported revenue of US$270.952 million, compared with US$302.086 million in the prior-year quarter. Quarterly report, statements of operations The quarterly MD&A attributes the decline primarily to the shorter period of Harvest activity included after the deconsolidation, with mature-market pricing pressure and other operating movements also affecting the comparison. Quarterly report, MD&A, June 30, 2026

The current quarter includes Harvest through June 3 and the consolidated medical platform for the remainder of June. Quarterly report, Note 4, quarter ended June 30, 2026 The comparative quarter retains the old perimeter. Consequently, the reported revenue decline is not a clean same-store decline and is not a clean measure of medical-only demand. Treating it as either would make the headline more definite than the disclosure permits.

For the first half ended June 30, 2026, revenue was US$557.706 million, compared with US$599.846 million in the corresponding first half of 2025. Quarterly report, statements of operations The longer reporting period includes more pre-separation activity, but it still mixes two scopes. A later quarter with an entirely post-separation perimeter will be easier to interpret operationally, while its year-over-year comparison will still require explanation.

The prior quarter ended March 31, 2026 had approximately US$287 million of revenue in the comparative earnings table. August 7, 2026 results A sequential decline from that level to the June quarter is not attributable entirely to demand or entirely to deconsolidation without a disclosed decomposition. The date at which revenue leaves the group is part of the calculation.

The annual baseline remains useful for identifying the prior economic pressures. Revenue in the year ended December 31, 2025 was US$1,181.180 million versus US$1,186.490 million in 2024; the annual MD&A describes lower retail sales from price compression, partly offset by higher traffic and units sold, and growth in wholesale and other revenue. Annual report, MD&A That history establishes that pricing pressure preceded the June restructuring.

A future revenue assessment should ask whether patient activity, product mix and realized prices support the remaining network. Management-service fees and new-market revenue should be identified separately where disclosed. An expanding market can still produce weaker economics if customers shift toward lower-priced products or promotional activity rises.

The next test has a date. On October 6, 2026 Trulieve said it will hold its third-quarter 2026 results call on Thursday, November 5, 2026, at 8:30 a.m. Eastern Time, following the release of results. Source →

The current filing does not restate the earlier group as a full medical-only comparative series. Any estimate that fills that gap requires assumptions. The figures here follow the disclosed scope and the company’s explanation rather than an invented organic growth rate for a perimeter that the available statements do not reconstruct.

06 Gross margin and adjusted EBITDA describe different levels of profit

Q2 2026 adjusted net income was $20 million, or $0.11 per diluted share, versus the reported continuing-operations loss of $405 million, or $2.10 per share. The adjusted measure excludes specified nonrecurring and deconsolidation effects and is distinct from GAAP earnings and operating cash flow. Trulieve second-quarter 2026 results release.

Gross profit in the quarter ended June 30, 2026 was US$162.289 million, or 59.9% of revenue, compared with US$182.926 million and 60.6% in the prior-year quarter. Quarterly report, MD&A reconciliation The margin remained broadly similar while the gross-profit dollars declined. A stable percentage does not replace the resources lost through a smaller revenue base.

Selling, general and administrative expense in the June 2026 quarter was US$101.767 million versus US$101.116 million a year earlier, increasing from 33.5% to 37.6% of revenue. Quarterly report, MD&A The company attributes the higher expense ratio to costs associated with the deconsolidation. Quarterly report, quarter ended June 30, 2026 The comparison still illustrates the risk that a smaller consolidated top line carries costs that do not fall at the same pace.

The June 2026 quarter’s US$370.523 million operating loss includes the US$403.333 million deconsolidation charge. Quarterly report, statements of operations Excluding that structural charge changes the interpretation materially, but removing it is not enough to establish a final recurring earnings measure. Taxes, financing, share-based compensation and other adjustments remain separate questions.

Adjusted EBITDA was US$97.996 million for the quarter ended June 30, 2026, compared with US$110.613 million in the prior-year quarter, with the company’s adjusted margin at 36.2% versus 36.6%. Quarterly report, non-GAAP reconciliation For the half-year ended June 30, 2026, adjusted EBITDA was US$198.418 million versus US$219.803 million. Quarterly report, non-GAAP reconciliation These are management-defined non-GAAP measures.

The reconciliation starts from the loss attributable to common shareholders and removes net financing items, tax expense and depreciation, then adds adjustments including the Harvest charge, equity-method loss, political contributions, transaction costs and share-based compensation. Quarterly report, reconciliation for periods ended June 30, 2026 Readers should distinguish a defensible removal of a structural accounting item from the broader decision to exclude costs that can still consume cash or dilute owners.

For the first half ended June 30, 2026, campaign and political contributions excluded from adjusted EBITDA were US$14.279 million, and acquisition, transaction and other non-recurring costs were US$19.752 million. Quarterly report, non-GAAP reconciliation A cost’s exclusion from adjusted EBITDA does not remove it from the company’s economic resources. Even genuinely temporary expenditure must be paid or settled.

The right comparison uses gross profit to examine product economics, operating expense to examine the platform’s cost and the cash-flow statement to examine funding. Adjusted EBITDA is useful as a supplemental measure of operating activity. Its usefulness falls when it is used as a substitute for cash, after-tax earnings or the obligations that sit outside the adjustment framework.

07 Operating cash is positive, but its quality needs context

Trulieve generated US$108.847 million of operating cash in the six months ended June 30, 2026, compared with US$137.224 million in the prior-year half. Quarterly report, cash-flow statement This is actual reported GAAP operating cash, rather than an adjusted earnings measure described with the word cash. It remains an important strength of the medical platform.

The August 7, 2026 release reports US$53.1 million of operating cash for the June quarter versus US$55.7 million for the March quarter, and company-defined free cash flow of US$32.1 million versus US$42.2 million. Quarterly results and free-cash-flow reconciliation The sequential figures make clear that positive generation does not imply an accelerating quarter.

For the first half ended June 30, 2026, the reported operating cash less US$34.495 million of capital expenditure produces a calculated US$74.352 million of free cash flow, consistent with the company’s rounded US$74.4 million measure. Quarterly cash-flow statement August 7, 2026 free-cash-flow reconciliation This calculation deducts capital expenditure. It does not reserve every possible tax settlement or remove all future financing and investment requirements.

The cash-flow statement adds back the US$403.333 million non-cash deconsolidation loss in the half-year ended June 30, 2026. Quarterly report, cash-flow statement That is why the large accounting loss is not an equivalent cash drain. The adjustment explains the reconciliation; it does not by itself demonstrate improvement in the recurring medical operation.

Another important part of the bridge is the US$60.955 million increase in uncertain tax position liabilities recorded in operating cash flow for the first half ended June 30, 2026. Quarterly report, cash-flow statement Expenses that build a liability rather than being paid immediately support reported operating cash in the current period. The economic obligation has not vanished. Its eventual payment, settlement or reversal requires separate evidence.

Inventory released approximately US$6.0 million of operating cash in the first half ended June 30, 2026, while other operating assets used approximately US$30.7 million. Quarterly report, cash-flow statement The much larger fall in balance-sheet inventory includes assets removed through Harvest deconsolidation and is not an equivalent working-capital cash release.

Cash generation is therefore real, but its interpretation requires the complete reconciliation. A favorable reading needs repeatable customer cash, manageable investment and a credible treatment of accumulated liabilities. A weak reading would treat every non-cash adjustment as a permanent benefit or assume that free cash flow already covers a dispute whose settlement date and amount remain uncertain.

08 The legacy tax dispute remains a material claim on resources

The treatment of the current medical business and the dispute over earlier tax years are separate matters. Trulieve’s June filing reflects the company’s interpretation of the medical rescheduling rule for the current tax year. It also retains a large liability for earlier uncertain tax positions. A favorable current treatment does not extend backward without evidence of a settlement, ruling or accounting recognition.

At June 30, 2026, uncertain tax position liabilities were US$598.187 million, compared with US$668.375 million at December 31, 2025. Quarterly report, balance sheet and Note 8 The lower balance is not evidence that the IRS accepted Trulieve’s legacy position. The note identifies the removal of approximately US$131.1 million associated with Harvest, partly offset by interest and other movements. Quarterly report, Note 8, first half ended June 30, 2026

Within the June 30, 2026 balance, the filing identifies US$583.1 million related to the company’s position on Section 280E, excluding US$65.1 million of claimed overpayments. Quarterly report, Note 8 A claimed overpayment is a tax position, not a refund already received. Likewise, the liability and the wider table of unrecognized tax benefits have different accounting scopes and are not interchangeable.

The June 30, 2026 note reports US$649.425 million of unrecognized tax benefits and approximately US$87.0 million of accrued interest within the uncertain-tax liability. Quarterly report, Note 8 The different totals are not a contradiction to be resolved by selecting the smaller figure. They describe distinct components and treatments in the tax accounting.

The quarterly legal disclosure says that IRS Revenue Agent Reports issued in September 2025 proposed taxes, interest and approximately US$38.1 million of penalties; the penalty amount is not included in the uncertain tax position liability. Quarterly report, legal proceedings as of June 30, 2026 Trulieve submitted protests to the IRS Independent Office of Appeals and says it believes its position is more likely than not to prevail. The same disclosure says the recognition threshold for reducing the legacy liability had not been met at June 30, 2026. Quarterly report, Note 8 and legal proceedings

This is the central limit on a simple net-cash narrative. The company has resources and generates operating cash, but it also has a disputed claim whose final amount and timing are not settled. Subtracting the entire liability immediately would ignore the unresolved legal process; ignoring it completely would ignore a recorded obligation.

The quarter ended June 30, 2026 had US$21.967 million of income-tax expense despite a substantial pretax loss affected by the Harvest transaction. Quarterly report, statements of operations and Note 8 The non-cash structural loss and the specific tax treatment explain why ordinary intuition about a positive tax benefit on an accounting loss can fail.

The analysis changes when the company reports a binding resolution or a recognized change in the liability, not when a headline about current rescheduling repeats. Until then, both the management position and the accounting restraint remain relevant to any scenario. Neither a promised refund nor a definite adverse payment is justified by the June disclosure.

09 Debt, leases and the cash balance must be read together

Cash and cash equivalents at June 30, 2026 were US$325.420 million, up from US$255.535 million at December 31, 2025. Quarterly report, balance sheet The increase does not equal operating cash retained after all activity. The first-half cash-flow statement also includes borrowing, capital expenditure and cash that left the consolidated group through Harvest.

In the six months ended June 30, 2026, cash disposed in the deconsolidation transaction was US$58.395 million and proceeds from long-term borrowings were US$60.742 million. Quarterly report, cash-flow statement The former is an investing cash outflow when the cash leaves the reporting perimeter; the latter is financing inflow. Both belong in the explanation of the closing cash balance.

At June 30, 2026, the private-placement notes had US$200 million of principal, a 10.5% stated coupon and a December 17, 2030 maturity, with a net carrying amount of US$195.820 million. Quarterly report, Note 6 Principal determines the contractual repayment claim, while the carrying amount reflects financing-cost accounting. A balance-sheet debt number is not necessarily the exact amount required to retire the instrument.

The earlier debt retirement is an important historical improvement. In December 2025, the company repaid the US$368 million principal of its former senior notes; the annual report says total cash used was approximately US$373 million including interest. Annual report, recent developments, December 2025 That retired maturity is no longer a current catalyst. The current debt structure nevertheless has a higher stated coupon on the replacement private notes.

Other notes had approximately US$94.551 million of principal at June 30, 2026, with US$93.571 million of net carrying value including current and non-current portions. Quarterly report, Note 6 The mortgage portfolio includes maturities across the following years, while the remaining small promissory obligation matures on October 24, 2026. Quarterly report, Note 6 as of June 30, 2026 Debt management therefore extends beyond a single long-dated bond.

At June 30, 2026, operating lease liabilities totaled a calculated US$97.064 million, finance leases US$69.978 million and construction-finance liabilities US$120.829 million, summing the current and non-current balance-sheet lines. Quarterly report, balance sheet These are separate categories of obligations. Their undiscounted future payments can include interest and are not an additional debt instrument on top of carrying values.

Management said in the August 7, 2026 quarterly filing that existing cash would meet anticipated requirements for at least the following year. Quarterly report, liquidity discussion That is a management liquidity assessment at the filing date, not a guarantee that all legal contingencies are resolved or that capital-market access will always remain favorable.

A robust reading gives credit for the cash balance and actual operating generation while retaining interest, capital spending, lease payments, tax uncertainty and market-entry costs. The existence of cash broadens the company’s options. The allocation of that cash determines how much flexibility persists.

On October 7, 2026 Trulieve said it had repaid, before maturity, about $65 million of mortgage notes secured by its cultivation site in Jefferson County, Florida, funded by operating cash, reducing outstanding debt to about $225 million. The release omits the rate and maturity, so the interest saving cannot be computed from it; the third-quarter report should show the new cash balance and debt schedule. Repaying debt with cash lowers leverage and interest but also the liquidity available for the Georgia and Texas expansion the company still plans to fund, subject to regulatory approvals. Company release

10 Medical rescheduling and the wider DEA process are different

The April 28, 2026 federal rule addresses the specified FDA-approved and state-licensed medical marijuana categories; it does not mean that every adult-use operation has become federally lawful. Federal medical rule That distinction helps explain why Trulieve separated mixed-use Harvest from its consolidated medical business rather than treating all former operations as interchangeable.

In the June 30, 2026 report, Trulieve says it applied for DEA registrations for its state-licensed medical operations in Florida, Pennsylvania, Georgia and West Virginia and describes its compliance position. Quarterly report, business and regulatory discussion These are the company’s disclosures. They do not provide a basis to state that every final registration has been issued when the filing describes applications and the registration process.

The DEA’s September 29, 2026 order stays the broader proposed rescheduling proceeding pending the identified process and sets a response deadline of October 13, 2026. DEA stay and briefing order The deadline concerns procedure. It is not a promised date for final adoption, and it does not convert the separate medical rule into a blanket adult-use authorization.

Commercial permission, tax treatment and stock-exchange eligibility interact, but they are not the same decision. A regulatory development can improve one part of the framework while leaving product, facility, distribution or filing requirements in place. The retained Harvest interest demonstrates how an exchange condition can remain relevant even after the medical framework changes.

A share-price move or an executive statement is not a basis for estimating a legal outcome. It distinguishes the issued rule, the company’s accounting position and the ongoing proceeding. The medical business may benefit from clearer treatment, but the tax liabilities for earlier years still require their own resolution.

For future updates, the useful evidence includes an issued registration or other relevant formal authorization, a company disclosure explaining its effect, and the next accounting treatment. A ceremonial milestone or a scheduled filing can attract attention; the operating consequence must be supported by the actual permission and financial disclosure.

11 Georgia expansion and the Connected agreement test execution

Georgia expanded its medical program effective July 1, 2026, according to the state commission’s current guidance. Georgia Access to Medical Cannabis Commission Trulieve’s July 1 announcement describes new products and shipments to independent pharmacies. Company Georgia announcement, July 1, 2026 Wider permitted access creates an operating opportunity, but dispensing and wholesale economics still determine the financial result.

The September 4, 2026 company announcement describes the opening of Dunwoody, with a celebration scheduled for September 10. Dunwoody announcement The state license list updated September 16, 2026 shows the Dunwoody dispensing license as active. Georgia license verification Those sources support a current operating development without using the June network count as though it had already included every subsequent location.

A wider pharmacy channel can reach patients outside Trulieve’s own stores. It can also change the mix of revenue and margin because the company does not retain the entire retail sale. The operating opportunity needs to be assessed through shipments, reorder behavior, receivable collection and the costs of supplying that channel. An expanded list of permitted products does not disclose those economics.

On September 28, 2026, Trulieve announced an exclusive, perpetual, royalty-free master license for Connected and Alien Labs genetics, marks and know-how in Florida and Texas. The release leaves Texas launch subject to final licensing and regulatory approval, gives only an opportunity to negotiate additional markets and does not disclose an upfront price. Connected agreement announcement Royalty-free describes the royalty term; it is not proof that the complete arrangement had no cost.

The Texas regulator’s December 1, 2025 conditional-selection announcement includes Trulieve and explicitly says conditional status does not permit cultivation, manufacturing, distribution or sales before final approval. Texas Department of Public Safety The company’s latest September 28, 2026 announcement retains that final-approval condition. Connected announcement The commercial agreement should therefore be described as preparation for a permitted launch, rather than evidence of current Texas revenue.

The operating mechanism is straightforward. Genetics and brand rights can give a cultivation platform differentiated products, but commercial value depends on consistent yield, product quality, realized price and repeat demand. A license cannot substitute for those outcomes. Exclusivity can protect the specified territory while the permitted product channel still constrains the addressable customer.

For the existing Florida platform, the test is whether the assortment supports profitable patient retention in a competitive market. For Texas, the first test is permission and readiness; only then do production, distribution and patient acquisition become reported operating questions. Keeping that sequence prevents a contractual announcement from becoming an unsupported revenue forecast.

12 Shares, buybacks and index access do not prove operating value

Finviz data as of September 30, 2026 show a US$10.90 reference price, US$2,098.96 million market capitalization, a share count of 169.98 million and 162.61 million float. Finviz data These figures are as of the date shown. The share count shown is not necessarily the total economic share count across all classes.

The June 30, 2026 accounts report 192,382,935 common-share equivalents on the as-converted basis used in the financial statements, while the July 31, 2026 cover data lists 170,158,916 subordinate shares and 22,406,386 subordinate equivalents represented by multiple-voting shares. Quarterly report, balance sheet, share note and cover Adding the July cover components gives a calculated 192,565,302 equivalents, rather than the smaller third-party figure. Quarterly report, cover as of July 31, 2026 Mixing a third-party quoted price, a single-class count and an all-class capitalization can create misleading valuation arithmetic.

On June 9, 2026, the board authorized repurchases up to the lesser of US$50 million or 8,495,038 subordinate shares, expiring June 16, 2027. Buyback filing No shares had been repurchased under that authorization by June 30, 2026, according to the quarterly note. Quarterly report, equity An authorization gives management discretion. It is not the same as completed purchases or a committed distribution of cash.

At June 30, 2026, the company had 5,287,412 options, 7,758,520 restricted share units and 327,274 performance share units outstanding, according to the equity note. Quarterly report, equity awards Outstanding awards can have exercise, vesting and settlement conditions. Their existence matters for potential dilution, but adding every award immediately to issued shares would also misstate the current position.

The August 24, 2026 post-effective registration amendments carry the existing shelf and employee-plan registrations into the Delaware successor framework. Shelf amendment Plan amendment The existence of registration documents does not mean a new cash financing has been completed. A subsequent offering requires its own terms, amount and closing evidence.

The September 22, 2026 issuer announcement says Trulieve was added to the S&P Total Market and Completion indices and their healthcare sector sub-indices. Index announcement Index access may broaden visibility, but the announcement does not establish a quantified inflow, a guaranteed valuation increase or membership in the S&P 500.

In the same September 30, 2026 market data, short float was 3.15%, institutional ownership 17.74% and insider ownership 15.55%. Finviz, dated data These figures are dated third-party snapshots with their own methodology. They do not reveal a current borrowing fee, a certain squeeze or the motives of any particular holder. Trading conditions belong alongside operating analysis rather than replacing it.

13 Delaware governance and the operating risks still matter

When the standalone chief accounting officer position was eliminated on June 30, 2026, Brett Walsh’s employment ended without cause. CFO Jan Reese became principal accounting officer on the same date, without additional compensation for that role. Trulieve SEC filing, June 30, 2026.

Trulieve completed its domestication from British Columbia to Delaware on August 11, 2026, after shareholder approval and the court order described in the filing. Domestication filing The share exchange was one-for-one into the corresponding Class A subordinate and Class B multiple-voting common stock. August 11, 2026 filing This is a completed corporate-law change, not a proposed future catalyst.

The same August 11, 2026 filing states that property, contractual rights, debts, liabilities and existing proceedings continue with the company. Domestication filing Moving jurisdiction does not erase a tax dispute or turn contractual liabilities into optional obligations. Its practical effects concern the corporate framework, investor access and the governing rights.

The June 25, 2026 definitive proxy describes the rights comparison and the multiple-voting structure on an as-converted basis. Definitive domestication proxy The multiple voting label does not by itself support an extreme voting control percentage; the conversion ratio and the ownership table are needed. Economic exposure and votes need the same denominator before a comparison is meaningful.

Management changes also belong in the context. The July 2, 2026 filing says the stand-alone chief accounting officer position was eliminated and CFO Jan Reese became principal accounting officer effective June 30. Accounting-officer filing That organizational change does not itself establish a control failure. Management concluded that disclosure controls were effective at June 30, 2026 in the quarterly report. Quarterly report, controls Effectiveness provides reasonable assurance, not certainty that every estimate or outcome will prove correct.

The remaining business risks are practical. Price competition can pressure gross profit, while agricultural production requires consistent quality and timely inventory turnover. A regulated product recall can interrupt revenue and create remediation cost. Florida concentration exposes the group to local demand and severe weather; expansion adds new staffing, production and compliance requirements.

The annual report identifies these operating, licensing, infrastructure and competitive risks for the year ended December 31, 2025. Annual report, risk factors Its older federal-law discussion needs the context of the subsequent medical rule and quarterly updates. Its description of manufacturing and market concentration remains useful for understanding why a regulatory improvement does not solve every operating problem.

The next financial period should give a clearer view of the post-separation medical platform. The events that materially change this analysis are collectible operating cash, transparent related-party balances, a formal tax development, final Texas permissions and disclosed results from the new channels. Their dates and evidence matter more than a perpetual promise that a catalyst is just around the corner.

The Health Score below is an editorial assessment of financial resources, catalysts, capital allocation, trading liquidity and operating execution. It recognizes actual cash generation while retaining tax uncertainty and the new reporting perimeter. It is not a valuation, a target price or a recommendation to buy or sell.